News

Penington Institute calls for strong action on pregabalin (Lyrica®)

Leading independent drug research, policy and education organisation Penington Institute is calling for state and federal government action to help reduce the number of overdose deaths resulting from the misuse of pregabalin (sold under the brand name Lyrica®). Pregabalin was subsidised on the Australian Pharmaceutical Benefits Scheme (PBS) as a treatment for nerve pain in [...]

By |June 14th, 2019|News|Comments Off on Penington Institute calls for strong action on pregabalin (Lyrica®)

Senior Communications Adviser

Penington Institute is seeking an experienced communications professional to join our advocacy team located in Carlton. Penington Institute advances health and community safety by connecting substance use research to practical action, promoting more effective, cost-efficient and compassionate ways to prevent and respond to problematic drug use. As Senior Communications Adviser you will be responsible for [...]

By |May 24th, 2019|News|Comments Off on Senior Communications Adviser

Australia’s dependence on prescription opioids should be new government’s top public health concern

One of the most urgent public health issues facing the new government will be Australia’s dependence on prescription opioids, independent drug research, policy and education organisation Melbourne-based Penington Institute, said today. Figures just released by the London-based Global Survey on Drugs show that the use of prescription opioids in the last year was highest in [...]

By |May 20th, 2019|News|Comments Off on Australia’s dependence on prescription opioids should be new government’s top public health concern

Lyrica®: Filling a pain gap or emerging threat?

Use of pregabalin (sold as Lyrica®) has skyrocketed in recent years. Anecdotal reports indicate problematic use is becoming more common including amongst people who inject drugs. In Australia, pregabalin is a commonly prescribed medicine, subsidised as an anti-epileptic and to treat neuropathic pain. It is often prescribed for the treatment of other conditions including musculoskeletal [...]

By |May 17th, 2019|News|Comments Off on Lyrica®: Filling a pain gap or emerging threat?

Penington Institute reflects on the achievements of former PM Bob Hawke

Leading independent drug research, policy and education organisation, Penington Institute, has today celebrated the public health achievements of Australia’s 23rd Prime Minister the Hon RJL Hawke AC GCL on the occasion of his passing. Penington Institute CEO John Ryan said that Bob Hawke can be thanked for many aspects of the health of Australians today. [...]

By |May 17th, 2019|News|Comments Off on Penington Institute reflects on the achievements of former PM Bob Hawke

Penington Institute urges Canberra to show ‘courage, imagination and boldness’ in tackling Australia’s opioid death rate

Leading independent drug research, policy and education organisation, Penington Institute, has welcomed today’s (27 February) announcement by the Commonwealth Government that it will fund a $7.2 million trial of naloxone access, the lifesaving drug capable of reversing opioid overdose. […]

By |February 27th, 2019|News|Comments Off on Penington Institute urges Canberra to show ‘courage, imagination and boldness’ in tackling Australia’s opioid death rate